Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Thirty-six patients with type 2 diabetes mellitus (T2DM) were randomized 1:1:1 to receive a once-daily oral dose of placebo or 150 or 300 mg of the dual SGLT1/SGLT2 inhibitor LX4211 for 28 days. Relative to placebo, LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglycerides. LX4211 also mediated trends for lower weight, lower blood pressure, and higher glucagon-like peptide-1 levels. In a follow-up single-dose study in 12 patients with T2DM, LX4211 (300 mg) significantly increased glucagon-like peptide-1 and peptide YY levels relative to pretreatment values, probably by delaying SGLT1-mediated intestinal glucose absorption. In both studies, LX4211 was well tolerated without evidence of increased gastrointestinal side effects. These data support further study of LX4211-mediated dual SGLT1/SGLT2 inhibition as a novel mechanism of action in the treatment of T2DM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400893 | PMC |
| http://dx.doi.org/10.1038/clpt.2012.58 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gliflozins in hypertension: basic mechanisms and clinical insights.
Am J Physiol Renal Physiol
July 2025
Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, United States.
Sodium-glucose cotransport (SGLT) inhibitors, or gliflozins, initially developed for managing type 2 diabetes mellitus, have emerged as promising therapeutic agents for hypertension, offering both cardiovascular and renal protection. Recently, a dual SGLT1/SGLT2 inhibitor was approved for the treatment of heart failure (HF), including preserved and reduced ejection fraction. Clinical trials consistently demonstrate the ability of gliflozins to lower blood pressure (BP) and reduce cardiovascular events, particularly in patients with comorbid conditions such as chronic kidney disease and HF.
View Article and Find Full Text PDFEffects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice.
Physiol Rep
April 2025
Division of Nephrology & Hypertension, Department of Medicine, University of California San Diego, and VA San Diego Healthcare System, San Diego, California, USA.
Dual inhibition of sodium glucose cotransporters 1 and 2 (SGLT1/SGLT2) by sotagliflozin protects the kidney and heart in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). To gain mechanistic insights, the current study aimed to establish a murine model of hypertensive CKD that shows cardio-renal protection by sotagliflozin. Since protection by SGLT2 inhibitors can be diabetes-independent, a nondiabetic murine model of subtotal nephrectomy with angiotensin II infusion-facilitated hypertension was followed for 7 weeks.
View Article and Find Full Text PDFA Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.
Clin Pharmacol Ther
June 2024
Prosciento, Inc., Chula Vista, California, USA.
Article Synopsis
- YG1699 is a new drug that inhibits the SGLT1 and SGLT2 transporters and was tested alongside dapagliflozin in a study involving adults with type 1 diabetes on insulin pump therapy.
- The trial involved a double-blind, 3-way crossover design where participants received different doses of YG1699 and dapagliflozin, with the main focus on how these drugs affected plasma glucose levels after meals.
- Results showed that YG1699 significantly lowered post-meal glucose levels and reduced insulin requirements compared to dapagliflozin, while the overall safety of both treatments appeared similar.
Comparison of SGLT1, SGLT2, and Dual Inhibitor biological activity in treating Type 2 Diabetes Mellitus.
Adv Ther (Weinh)
December 2023
Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ, 07102.
Diabetes Mellitus Type 2 (T2D) is an emerging health burden in the USand worldwide, impacting approximately 15% of Americans. Current front-line therapeutics for T2D patients include sulfonylureas that act to reduce A1C and/or fasting blood glucose levels, or Metformin that antagonizes the action of glucagon to reduce hepatic glucose production. Next generation glucomodulatory therapeutics target members of the high-affinity glucose transporter Sodium-Glucose-Linked-Transporter (SGLT) family.
View Article and Find Full Text PDFEffects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
Am J Cardiovasc Drugs
May 2022
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Article Synopsis
- * A thorough search of clinical trial databases revealed 111 studies with over 103,000 patients, focusing on differences in outcomes for type 1 and type 2 diabetes.
- * Results indicated that while SGLT1/2 inhibitors reduced the risk of heart attack and stroke in type 2 diabetes patients, SGLT2 inhibitors were more effective at lowering HbA1c levels; however, SGLT1/2 inhibitors had a higher risk of